国产亚洲欧美日韩俺去了,人妻无码久久精品,亚洲人成影院在线观看,亚洲AV永久无码精品表情包

 辰欣藥業(yè) Cisen Pharmaceutical   
辰欣藥業(yè)股份有限公司是一家綜合性化學(xué)藥品制劑生產(chǎn)企業(yè)。公司現為國家級高新技術(shù)企業(yè)、博士后科研工作站、山東省泰山學(xué)者藥學(xué)特聘專(zhuān)家設崗單位、山東省企業(yè)技術(shù)中心、山東省抗生素工程技術(shù)研究中心，獲得國家發(fā)改委產(chǎn)業(yè)化扶持基金、國家科技部科技型企業(yè)技術(shù)創(chuàng )新基金、中國專(zhuān)利山東明星企業(yè)等榮譽(yù)。2011年5月，“辰欣”商標被國家工商總局認定為“中國馳名商標”，同時(shí)入選2011中國醫藥研發(fā)產(chǎn)品線(xiàn)最佳工業(yè)企業(yè)及2011年中國醫藥工業(yè)最具投資價(jià)值企業(yè)。
　　公司秉承“推陳出新、誠實(shí)守信”的企業(yè)理念，堅持以科技為先導，以質(zhì)量求生存，以創(chuàng )新求發(fā)展，走出了一條科技創(chuàng )新之路，先后投資建成了開(kāi)發(fā)區第一工業(yè)園十五個(gè)生產(chǎn)車(chē)間和現代化的動(dòng)物實(shí)驗樓及大型高架立體倉庫。2010年6月辰欣第二工業(yè)園隆重奠基，加速了辰欣藥業(yè)向工藝難度大、生命周期長(cháng)、附加值高的新產(chǎn)品進(jìn)軍的步伐。公司可生產(chǎn)大輸液（非 PVC 軟袋輸液、塑料瓶輸液、玻璃瓶輸液）、水針、凍干粉針、片劑、膏劑、滴眼劑、膠囊劑和小原料藥等八大劑型近 400個(gè)規格的產(chǎn)品。其中，輸液被評為山東省名牌產(chǎn)品，輸液產(chǎn)品產(chǎn)量位居國內單廠(chǎng)第一，水針產(chǎn)量居山東省第一位。
　　辰欣藥業(yè)以保障和提高病患者生命健康質(zhì)量為己任，致力于自主研發(fā)、生產(chǎn)能夠填補國內空白的藥品。每年將銷(xiāo)售收入的6%用于科技研發(fā)投入，先后與中國藥科大學(xué)、沈陽(yáng)藥科大學(xué)、山東大學(xué)、山東省醫科院、山東省醫藥工業(yè)研究所、中科院藥物研究所、軍事醫學(xué)科學(xué)院等科研院所建立了長(cháng)期合作關(guān)系，成功走出了一條“產(chǎn)、學(xué)、研聯(lián)合創(chuàng )新”的路子，建立了從市場(chǎng)調研、開(kāi)發(fā)設計到試制生產(chǎn)的一條龍開(kāi)發(fā)體系，形成了研制一代、儲備一代、生產(chǎn)一代的良性循環(huán)。 新產(chǎn)品涵蓋了心腦血管類(lèi)、抗菌、抗病毒類(lèi)、抗癌類(lèi)等多門(mén)類(lèi)100多個(gè)品種。其中，由辰欣藥業(yè)自主研制的阿德福韋酯（原料及片劑）被評為國家一類(lèi)新藥證書(shū)，獲得山東省科技進(jìn)步一等獎，并獲得國家科技部、省、市科技創(chuàng )新基金扶持。該藥物的研制成功是我國在自主研發(fā)乙肝藥物治療領(lǐng)域取得的重大突破，對于推動(dòng)我國醫藥產(chǎn)業(yè)的技術(shù)進(jìn)步，加快我國醫藥高技術(shù)成果產(chǎn)業(yè)化，提高我國生物醫藥產(chǎn)業(yè)技術(shù)創(chuàng )新能力和國際競爭力具有重要意義，也將是辰欣品牌再次提升的發(fā)動(dòng)機。
　　辰欣藥業(yè)非常重視產(chǎn)品的質(zhì)量管理工作。我們堅持“質(zhì)量第一，預防為主”的質(zhì)量管理方針，秉承“藥因質(zhì)盛，業(yè)以牌榮”的質(zhì)量管理理念，建立了一整套縝密有效的質(zhì)量保證體系，總經(jīng)理對產(chǎn)品質(zhì)量全面負責，公司質(zhì)量保證部向各車(chē)間派駐質(zhì)量員，對車(chē)間生產(chǎn)質(zhì)量管理工作進(jìn)行監督指導，使質(zhì)量否決權落到實(shí)處。各車(chē)間在生產(chǎn)崗位設置工藝監控點(diǎn)，嚴把質(zhì)量檢驗監督關(guān)。目前，公司所有劑型的產(chǎn)品全部通過(guò)了國家食品藥品監督管理局認證中心 GMP 認證和三體系認證，并被山東省企業(yè)聯(lián)合會(huì )評定為山東省質(zhì)量管理和現場(chǎng)管理樣板單位。
　　十二五期間，辰欣藥業(yè)將繼續以科技創(chuàng )新為首要工作，通過(guò)引進(jìn)戰略投資者、上市、合資、增資等多種形式進(jìn)行融資，增加新產(chǎn)品研發(fā)投入，提高新產(chǎn)品技術(shù)含量，努力實(shí)現2015年銷(xiāo)售收入100億元，利稅20億元的宏偉目標，為中國醫藥事業(yè)的發(fā)展做出更大的貢獻！

Cisen Pharmaceutical Co., Ltd. is a comprehensive chemical pharmaceutical enterprise. The company has developed into a national hi-tech enterprise, which owns a Post-Doctoral Research workstation, Shandong Taishan scholar posts for Specially Hired specialist on medicines, center of enterprise technology of Shandong and antibiotics engineering technology research center of Shandong, obtains National Development and Reform Committee Industrialization support funds, Shandong Star Enterprise of Chinese Patent etc. The logo of Cisen has been appraised as China famous trademark by SAIC, meanwhile, the company has been selected as the best industrial enterprise of R&D product line of China's Pharmaceutical and enterprise with the best investment value of China's pharmaceutical industry in 2011. Cisen is committed to “Innovation and Integrity”, which is considered as a core value of Cisen. Cisen always adheres to the science and technology as the guide, survive by quality, develop by innovation, forming a path of technological innovation. The company has successively invested and built the first Cisen industrial park, 15 production workshops, and elevated 3-dimensional storehouse. Cisen second industrial park held its grand groundbreaking ceremony on 19 June 2010. The construction of Cisen second industrial park quicken its pace of producing new products with difficult technology, long life cycle, intensive capital and high added value. The company can produce infusion solution(non PVC soft bag infusions, plastic bottle infusions, glass bottle infusions), injection, lyophilized powder injections, tablets, ointments, eye drops, capsules and API etc, 8 series nearly 400 varieties products. Among which, the infusion solution products have been appraised by Shandong province as a famous brand, the single factory capacity of infusion solution ranks No.1 in China and the capacity ranks No.1 in Shandong province. Cisen Pharmaceutical Co., Ltd regards safeguard and promotion for health quality of patients as its own duty and devotes to independently develop and produce drugs to fill the domestic void. Cisen spends 6% of annual sales revenue in its technology research. Cisen has established a strategic relationships with the Pharmaceutical University, Shenyang Pharmaceutical University, Shandong University, Shandong Academy of Medical Sciences, Shandong Institute of pharmaceutical Industry, Institute of Pharmacology under Chinese Sciences, Academy of Military Medical Sciences and other domestic colleges; the company has developed a joint innovation system of “Industry-study-research”. Cisen has established a coordinated process of “Market research-Development and design-Trial production ”and has formed a virtuous cycle of “Develop-Reserve-Production”. New drugs include many category of and more than 100 drugs, such as cardiovascular type, antibacterial, antiviral, anticancer, and so on. Particularly, the anti-HBV Adefovir Dipivoxil Tablets(APIs and tablet) that the company has developed obtains the certificate of State First-Class Innovative Drug, the first prize of technological advancement of Shandong and technological innovation support fund from municipal government, provincial government and Ministry of Science and Technology. The successful development of this drug is a major breakthrough of independent development in the field of HBV drug treatment in China, what has a great significance in promoting technology advancement of China's pharmaceutical industry, quickening the industrialization of China's hi-tech achievements, improving the technology innovation ability of China's pharmaceutical industry and international competitiveness. It will become the engine for promoting the brand value of Cisen as well.